Maslow ASL, Guarnaccia M, Stefanacci C, et al. - Researchers examined if GnRH-agonist trigger results in similar maturity rate (MR) in low and normal responders compared with high responders in women undergoing planned oocyte cryopreservation, for whom even a small risk of ovarian hyperstimulation syndrome may not be acceptable. They performed a retrospective cohort study of 1,189 individuals including all planned oocyte cryopreservation cycles conducted at a large, single center, oocyte cryopreservation program from April 2016 to December 2018. Inclusion of 1,680 cycles was done in the study. GnRH-agonist was utilized for trigger in a total of 57.1% (959/1,680) utilized. Peak estradiol (E2) < 3,000, was noted in a total of 611 cycles (63.7%) and E2 > 3,000 was noted in 331 (34.5%). Maturity rate did not differ between cycles with E2 levels > 3,000 pg/mL and < 3,000 pg/mL. This confirms confirming the non-inferiority of maturity rates with GnRH-agonist triggers in cycles with peak E2 < 3,000 pg/mL. While lower peak E2 levels were observed to be correlated with lower mean oocytes retrieved and mean MII oocytes; no significant difference was observed in maturity rate amongst E2 level groups. Lower MR was noted in cycles with E2 < 1,000 pg/mL; this was observed irrespective of trigger type. Per these outcomes, GnRH-agonist seems to be a relevant option for final maturation of oocytes in planned oocyte cryopreservation; this was identified regardless of response to stimulation or risk of ovarian hyperstimulation syndrome.